Low-dose IL-2 therapy limits the reduction in absolute numbers of circulating regulatory T cells in rheumatoid arthritis.
Sheng-Xiao ZhangJia WangCai-Hong WangRui-Huan JiaMing YanFang-Yuan HuGuang-Ying LiuXue-Yu LiuJing LuoChong GaoXiao-Feng LiPublished in: Therapeutic advances in musculoskeletal disease (2021)
Low-dose IL-2 treatment for rheumatoid arthritis • Circulating Tregs may be involved in the pathogenesis and progression of RA.• The absolute count of Tregs was significantly correlated with disease activity measures.• Low-dose IL-2 was able to effectively expade Tregs and help for RA patients' symptoms remission without evaluated side effects.
Keyphrases
- disease activity
- rheumatoid arthritis
- low dose
- regulatory t cells
- systemic lupus erythematosus
- rheumatoid arthritis patients
- ankylosing spondylitis
- high dose
- juvenile idiopathic arthritis
- end stage renal disease
- interstitial lung disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- dendritic cells
- stem cells
- prognostic factors
- peritoneal dialysis
- peripheral blood
- patient reported outcomes
- physical activity
- immune response
- cell therapy